Cesca Therapeutics Inc (NASDAQ:KOOL) rose 10.3% on Wednesday . The company traded as high as $4.30 and last traded at $4.18, approximately 303,269 shares changed hands during mid-day trading. An increase of 184% from the average daily volume of 106,801 shares. The stock had previously closed at $3.79.

A number of brokerages have issued reports on KOOL. HC Wainwright reiterated a “buy” rating and set a $6.50 price target (up previously from $1.00) on shares of Cesca Therapeutics in a research report on Wednesday, August 14th. ValuEngine raised Cesca Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd. Finally, Zacks Investment Research upgraded Cesca Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Tuesday, August 20th.

The company has a market cap of $9.91 million, a PE ratio of -1.16 and a beta of 0.94. The firm’s fifty day moving average is $3.09 and its 200 day moving average is $1.68. The company has a current ratio of 1.52, a quick ratio of 0.91 and a debt-to-equity ratio of 0.50.

Cesca Therapeutics (NASDAQ:KOOL) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.13. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. The business had revenue of $4.31 million for the quarter, compared to the consensus estimate of $3.40 million. As a group, sell-side analysts anticipate that Cesca Therapeutics Inc will post -0.45 EPS for the current fiscal year.

Cesca Therapeutics Company Profile (NASDAQ:KOOL)

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Recommended Story: What is the downside to momentum investing?

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.